Taken together, the results of this study demonstrated that (i) FOXM1 expression was high in AFP-positive HCC and (ii) the proteasome inhibitor carfilzomib suppressed FOXM1 expression and showed antitumor effects on AFP-positive HCC. The gene discussed is FOXM1; the disease is hepatocellular carcinoma.